HITV Lab

Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

Home HITV Cancer Therapy Clinical Trials

Thursday29 June 2017

Clinical Trials

How Successful is HITV Treatment?

How Successful is HITV Treatment?

Combining immunotherapy with radiation was shown to successfully eliminate metastatic and recurrent tumors on initial treatment in 21 of 26 patients with 13 of the 26 having no evidence of recurrent disease when evaluated by PET-CT at various intervals of follow-up.

The overall disease-free interval of the responding patients at the current time is 377 days. This remarkable response supports the concept that combinations of conventional anti-cancer therapies and cancer immunotherapy are worthy of investigation in patients with advanced cancers as well as in patients that are undergoing primary adjunctive therapy for their disease.

Read More about HITV Cancer Therapy

HITV Lab

HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks